Fidaxomicin versus Vancomycin forClostridium difficileInfection (Q34162172)

31 July 2017

title

Fidaxomicin versus vancomycin for Clostridium difficile infection (English)

1 reference

31 July 2017

Fidaxomicin versus Vancomycin forClostridium difficileInfection (English)

1 reference

Crossref

https://api.crossref.org/works/10.1056/NEJMOA0910812

23 November 2024

main subject

Clostridium difficile

0 references

1 reference

Karl Weiss

1 reference

31 July 2017

Arnold Lentnek

1 reference

31 July 2017

Yoav Golan

1 reference

31 July 2017

Sherwood Gorbach

1 reference

31 July 2017

Pamela Sears

1 reference

31 July 2017

Youe-Kong Shue

1 reference

31 July 2017

OPT-80-003 Clinical Study Group

1 reference

31 July 2017

Thomas J. Louie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21288078

23 November 2024

Mark A. Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21288078

23 November 2024

Kathleen M. Mullane

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21288078

23 November 2024

language of work or name

English

0 references

publication date

1 February 2011

1 reference

31 July 2017

3 February 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21288078

full work available at URL

23 November 2024

http://content.nejm.org/cgi/content/abstract/364/5/422

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21288078

http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812

23 November 2024

1 reference

Crossref

https://api.crossref.org/works/10.1056/NEJMOA0910812

The New England Journal of Medicine

23 November 2024

published in

1 reference

31 July 2017

volume

364

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

422-431

1 reference

An epidemic, toxin gene-variant strain of Clostridium difficile

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Clostridium difficile--more difficult than ever

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Clostridium difficile-Associated Diarrhea and Colitis

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Recurrent clostridium difficile

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

In vitro activity of OPT-80 against Clostridium difficile

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-rep

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

Cochrane Database of Systematic Reviews

23 November 2024

CD004610

Nelson R

2007

1 reference

Crossref

https://api.crossref.org/works/10.1056/NEJMOA0910812

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

23 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA0910812

23 November 2024

Identifiers

1 reference

31 July 2017

1 reference